CN Patent

CN112569357B — 双重内皮素受体拮抗剂与利尿剂的组合物

Assigned to Shenzhen Ausa Pharmed Co ltd · Expires 2023-03-28 · 3y expired

What this patent protects

本发明提供一种治疗肺动脉高压的药物组合物，由双重内皮素受体拮抗剂、吲达帕胺及药剂学上可接受的载体组成。本发明提供的药物组合物可以有效降低肺动脉高压，并且能减少单一活性成份的副作用；另外，本药物组合物还可以使患者服药方便，提高依从性。

USPTO Abstract

本发明提供一种治疗肺动脉高压的药物组合物，由双重内皮素受体拮抗剂、吲达帕胺及药剂学上可接受的载体组成。本发明提供的药物组合物可以有效降低肺动脉高压，并且能减少单一活性成份的副作用；另外，本药物组合物还可以使患者服药方便，提高依从性。

Drugs covered by this patent

Patent Metadata

Patent number
CN112569357B
Jurisdiction
CN
Classification
—
Expires
2023-03-28
Drug substance claim
No
Drug product claim
No
Assignee
Shenzhen Ausa Pharmed Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.